Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into cells (excluding immune cells) is provided by the present invention. Specifically, a system for delivering a target substance into a cell (excluding immune cells), including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid, a protein or a low-molecular-weight compound into a cell (excluding immune cells) by using the ultrafine bubble water, etc.; and the like are provided.

Abstract: A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into immune cells such as T cell and the like is provided by the present invention. Thus, a system for delivering a target substance into an immune cell, including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid or a protein into an immune cell by using the ultrafine bubble water, etc. and ultrasound; and the like are provided.

Abstract: The present invention provides a safer novel opening system with highly broad utility for a blood-brain barrier (BBB), containing nano-bubble water or nano-bubble aqueous solution containing nano-bubbles having an average diameter of not more than 200 nm, and an ultrasound generating apparatus in combination; a method for opening BBB, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound; and a method for increasing BBB permeability of a drug, including using the nano-bubble water or nano-bubble aqueous solution, and an ultrasound.

Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.

Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.

Abstract: A controlled release composition for oral administration, which comprises a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing a polymer, is provided.

Abstract: A controlled release composition for oral administration, which comprises a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing a polymer, is provided.

Abstract: A hydrophilic membrane having a low adsorptivity for a protein is disposed, as an interface, on a side to be contacted with a skin, and a drug such as a physiologically active peptide is transdermally delivered by iontophoresis. The membrane has an adsorptivity for a protein of not greater than 10 &mgr;g/cm2. The thickness of the membrane is about 10 to 200 &mgr;m, and the porosity of the membrane is about 60 to 90%. Such membrane includes a hydrophilized fluororesin membrane, a hydrophilized polysulfone membrane and a hydrophilized cellulose derivative membrane.

Abstract: It is made possible wherein, concerning problem points in regard to which a learner would like improvement, at the time that such are compared with those of an instructor, the model performance of the instructor can be precisely accessed as images. Moreover, it is made possible wherein the above described model performance of the instructor can be displayed in diagrammatic representation and/or letters or speech sound.

Abstract: A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density. The method insures excellent pharmacologic efficacy with a low risk for side effects in the prevention and therapy of (1) angina pectoris, (2) unstable angina and (3) ischemic complications and coronary arterial reocclusion or restenosis associated with PTCA or coronary thrombolysis.

Abstract: The present invention relates to a pharmaceutical composition for oral administration in which a fumagillol derivative is stabilized and exhibits remarkable antiangiogenesis activity in oral administration.

Abstract: A calcitonin, its derivative or a salt thereof is transdermally delivered by iontophoresis in which a substantially constant voltage in the range of 3 to 20 V is applied at an electric current of 0.05 to 0.5 mA/cm.sup.2. In this process, the calcitonin can be delivered transdermally with a higher absorptivity by applying a higher voltage for a short period (at a voltage of about 6 to 14 V for about 5 to 15 minutes) in the initial stage of the voltage application, and then applying a lower voltage for a long period (at a voltage of about 3 to 9 V for about 30 to 40 minutes).

Abstract: A pharmaceutical composition having improved stability which comprises a fumagillol derivative and a fatty acid ester of glycerin or polyglycerin is disclosed. The composition is useful for treating diseases associated with angiogenesis such as hepatoma, etc.